Biogen/Capsigen Ink Up To $1.3bn Deal For Improved AAV Capsids
Collaboration Is Latest Focused On Next-Generation Gene Therapies
Executive Summary
Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.
You may also be interested in...
Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology
Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.
Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD
Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.
Deal Watch: Roche To Try Pieris’s Anticalins In Respiratory, Ophthalmic Indications
Pieris and Genentech try partnering again after a disappointing IO tie-up before. Biogen’s hectic May includes partnerships with Ginkgo, Envisagenics, Capsigen and an opt-in on TMS’s stroke candidate.